Downregulation of VDAC1 and/or prevention of its interaction with Aβ and phosphorylated Tau could potentially preserve mitochondrial function, slow AD progression, and ultimately improve cognitive function in AD patients [184,188]. Here, MAPT is linked to Alzheimer disease.